Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 25

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 25
---
, without limitation, a device, compound, kit, biomarker or service that contains a component that is used to detect or quantify the presence or amount of an analyte in body or tissue that affects the pathogens of the condition).

“ CD47 Product ” means any past and future product developed and to be developed using CD47 antibody drugs.

“ Class B Common Stock” means the Class B common stock, par value $0.0001 per share, of Iris.

“ closing” means the closing of the Transactions.

“ Closing Date” means the date on which the Business Combination is consummated.

“Code” means the Internal Revenue Code of 1986, as amended and restated from time to time.

“ Combined Company” means ParentCo and its consolidated subsidiaries after giving effect to the Business Combination.

“Convertible Note Subscription Agreement” means that certain Convertible Note Subscription Agreement, dated November 30, 2022, by and among ParentCo, Iris, and the PIPE Subscriber, as amended.

“DGCL” means the General Corporation Law of the State of Delaware.

“Effective Time” means the effective time of the Mergers.

“ Existing Bylaws ” means the current amended and restated bylaws of Iris.

“Forfeiture Agreement” means that certain Sponsor Forfeiture Agreement, dated November 30, 2022, by and between Iris and Sponsor.

“ GCC Vaccine Product ” means a prophylactic or therapeutic agent, that acts by inducing an immune response directed specifically against the Guanylyl Cyclase C (“GCC”) antigen.

“ HSR Act ” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

“ Incentive Plan ” means the ParentCo 2024 Omnibus Equity Incentive Plan.

“ initial stockholders ” or “ initial holders ” means the Sponsor and any other holders of Founder Shares prior to the IPO (or their permitted transferees).

“ InnoBation License ” means the License and Development Agreement entered into as of March 30, 2022, by and between InnoBation Bio Co., Ltd., a Korean company, as licensor (“InnoBation”) and Valetudo Therapeutics LLC, a Delaware company, as licensee (“Valetudo”) covering the license of certain patents and know-how with respect to the CD47 Products, which license was assigned by Valetudo to Liminatus pursuant to the Valetudo Assignment.

“ IPO ” means Iris’s initial public offering, consum